MultiGen's Modified Sanger Sequencing Takes Aim at Detecting Cancers, Infectious Diseases

NEW YORK (360Dx) – An allele-specific multiplex sequencing (ASMS) assay that can identify low concentrations of relevant drug targets could provide clinical support in identifying and prescribing appropriate chemotherapeutic drugs, and it has potential for routine clinical use in a far broader scope of applications, according to its developer MultiGen Diagnostics.

In a study conducted with the department of pathology at Mount Sinai School of Medicine, and published online in the Journal of Solid Tumors, MultiGen reported that its ASMS test identified and confirmed the BRAF p.V600E mutation with a thousandfold increase in sensitivity compared to competing PCR-based and next-generation sequencng methods.

Testing for BRAF p.V600E is an expected practice prior to starting drug therapy for melanomas, papillary thyroid cancer, and other cancers, and the presence of the mutation predicts for better treatment success with BRAF kinase inhibitors such as Zelboraf (vemurafenib), MultiGen said.

Its Founder and Chief Scientific Officer Thurai Moorthy said in a statement that the ASMS assay, which is a modification of traditional Sanger sequencing, provides a sensitive companion diagnostic for the detection of cancer mutations, and that the BRAF mutation project is a “generic demonstration” of capabilities that could immediately translate into “many more patients qualifying

Be the first to comment

Leave a Reply

Your email address will not be published.


*